Physician profile
Jack E Cribb
NPI 1497961635
$21,348.08
in general payments reported to CMS, 2019-2025
49 companies · $1,896 in 2025
The $1,896 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,590 · 2020: $2,368 · 2021: $2,691 · 2022: $1,903 · 2023: $1,643 · 2024: $1,258 · 2025: $1,896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,785 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,784.53 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $7,877.57 | 2019-2022 | |
| Novo Nordisk INC | $3,037.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $951.31 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $938.60 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Sanofi-Aventis U.S. LLC | $729.27 | 2019-2022 | |
| Eisai INC. | $720.78 | 2021-2025 | |
| Pfizer INC. | $720.17 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $590.02 | 2019-2022 | |
| Axsome Therapeutics, INC. | $486.89 | 2022-2025 | Sunosi, Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $486.60 | 2019-2025 | Jardiance |
| Abbvie INC. | $483.21 | 2021-2025 | Vraylar, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $456.26 | 2021-2025 | |
| Amgen INC. | $350.21 | 2019-2023 | Repatha, Otezla, Prolia |
| Janssen Pharmaceuticals, INC | $316.52 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $312.41 | 2019-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Cribb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.